Research integrity in the COVID-19 era: insights from Retraction Watch co-founder Ivan Oransky
Read Ivan Oransky’s take on the retraction landscape and his perspectives on how to tackle research integrity issues in the future.
Overcoming barriers to reporting negative data: perspectives from the Center for Biomedical Research Transparency’s founder
Sandra Petty discusses the Null Hypothesis Initiative and looks to the future of reporting negative data.
Reporting of many clinical trials ruled illegal
A US court ruling finds reporting of many clinical trials of unapproved drugs in breach of the law. But responses to the ruling are uncertain.
Is preregistering scientific research becoming mainstream?
PLOS ONE now offers Registered Reports, shifting peer review focus from results to the quality of study design. Is this part of the future of open science?
Negative results can have a positive impact, but only if they are available!
The reproducibility crisis is linked to publication bias and a paucity of negative data. Find out how and why to get such data published.
Disparities claimed between stance and action on clinical trial outcome reporting by top medical journals
Selective reporting of clinical trial outcomes may be widespread. This study reports instances occurring in CONSORT-endorsing medical journals.
Can holding institution heads to account lead to improved rates of clinical trial reporting?
AllTrials seeks support for a new initiative to monitor clinical trial reporting in the UK.
The fifth edition of the STM report
The fifth edition of the STM report provides an in-depth review of current issues and recent trends within the scientific and scholarly publishing industry.
Increasing quality and transparency of preclinical data: an opportunity for publication professionals?
An article in the MAP newsletter examines how publication professionals could help to increase preclinical publishing standards.
How to overcome the issue of poorly reported clinical trial outcomes
A number of initiatives developed to prevent researchers from only reporting the most impressive outcomes of clinical trials are explored in an opinion piece from The BMJ.
The elimination of negative study results: reporting and citation bias
Is the apparent efficacy of treatments being altered by bias? A recent study takes a closer look at the cumulative effects of reporting and citation biases.
New EU trials tracker reveals that half of European clinical trials have broken reporting rules
Is your institute breaking European clinical trial reporting rules? Find out using the new EU trials tracker, part of the AllTrials initiative.
Inferential statistics and false conclusions: is the p value to blame?
Significance testing and p values are widely used in medical publications, but just how meaningful are they?
Meeting report: summary of the 14th Annual Meeting of ISMPP – Part 2
Missed the 14th Annual Meeting of ISMPP? Read the second part of our meeting report to get up to speed!
Clinical trial transparency: are non-commercial funders lagging behind industry sponsors?
A new study from the AllTrials team sheds light on clinical trial reporting rates by non-industry sponsors.
A new series from The BMJ highlights unreported trials
A new, regular series in The BMJ will highlight a different unreported clinical trial every week, with the intention of improving reporting rates.